Institut für Frauengesundheit GmbH

Effect of delayed isolation of peripheral blood mononuclear cells on cell viability and functionality (2025) Lehle S, Völkl S, Seitz K, Goossens C, Emons J, Rübner M, Uhrig S, et al. Journal article The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer – the SERAPHINA study (2025) Schneeweiss A, Fasching P, Thill M, van Mackelenbergh M, Marme F, Tesch H, Fehm TN, et al. Journal article Impact of risk and lifestyle factors on therapy goals in the treatment of breast cancer and gynecological cancer patients with integrative medicine (2025) Seitz K, Theuser AK, Antoniadis S, Beckmann M, Beierlein M, Brückner L, Au K, Hack C Journal article Validation of the Questionnaire for the Structured Assessment of the Use of Complementary Medicine Methods and Procedures in Patients from the S3 Guideline Complementary Medicine in Oncology and Practical Use of it in Patients with Gynecological Cancer Validierung des Fragebogens f r die strukturierte Bewertung der Nutzung komplement rmedizinischer Methoden und Verfahren aus der S3-Leitlinie zur Komplement rmedizin in der Onkologie und praktischer Einsatz bei Patientinnen mit gyn kologischem Krebs (2025) Seitz K, Theuser AK, Hack C, Fasching P, Emons J, Brückner L, Au K, et al. Journal article Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial (2025) Beierlein M, Häberle L, Nabieva N, Maass N, Aktas B, Kümmel S, Thomssen C, et al. Journal article Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole (2024) Fasching P, Hack C, Nabieva N, Maass N, Aktas B, Kümmel S, Thomssen C, et al. Journal article Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer (2024) Gaß P, Thiel FC, Häberle L, Ackermann S, Theuser AK, Hummel N, Boehm S, et al. Journal article Impact of the Corona Pandemic on Cervical Cancer Screening Assessment (2024) Stübs F, Behrens A, Seibold A, Adler W, Geppert CI, Hartmann A, Knöll A, et al. Journal article Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study (2023) Hack C, Maass N, Aktas B, Kümmel S, Thomssen C, Wolf C, Kolberg HC, et al. Journal article Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – A single-arm phase II trial (NeoImmunoboost, AGO-B-041) (2023) Fasching P, Hein A, Kolberg HC, Häberle L, Uhrig S, Rübner M, Belleville E, et al. Journal article